Characteristics of long-term gastric cancer survivors ID'd

September 7, 2012
Characteristics of long-term gastric cancer survivors ID'd
Patients with gastric and gastroesophageal junction cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

(HealthDay)—Patients with gastric and gastroesophageal junction (GEJ) cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those who do not survive, according to research published online Sept. 4 in the Journal of Clinical Oncology.

Pamela L. Kunz, M.D., of the Stanford University School of Medicine in California, and colleagues conducted a population-based study involving 47,647 patients diagnosed with gastric or GEJ adenocarcinoma between 1988 and 2005 who were part of the California Cancer Registry, a member of the 's Surveillance, Epidemiology, and End Results program.

Overall, only 20 percent of patients survived at least three years. The researchers found that longer survival correlated with several factors, including earlier stage, surgery, chemotherapy, radiation, intestinal histology, well- or moderately-differentiated tumors, race (Asian/Pacific Islander and Hispanic), gender (female), socioeconomic status (highest quintile), treatment at an , anatomic location (fundus/body/antrum), and hospital size (more than 150 beds). Patients with tumors originating in the fundus/body/antrum had longer median disease-specific survival compared to those with tumors originating in the esophagus/cardia (13.4 versus 10.8 months). Median disease-specific survival was significantly longer for intestinal histology (28.9 months) compared with other (11.0 months) or diffuse histology (10.1 months).

"This large population-based study will serve as a platform for developing future work to better understand factors involved in long-term survivors of , including genetic, genomic, and survivorship studies," the authors write.

Explore further: Probability of long-term glioblastoma survival assessed

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Probability of long-term glioblastoma survival assessed

May 28, 2012
(HealthDay) -- Although the overall mortality rate of glioblastoma is high, compared with patients newly diagnosed with glioblastoma, those who survive two years or more after diagnosis have a favorable conditional probability ...

Asian lung cancer patient survival exceeds Caucasians' on multiple regimens

June 1, 2011
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...

Adjuvant radiochemotherapy has lasting benefit in gastric cancer

May 18, 2012
(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free ...

Chemo combo promising for pancreatic neuroendocrine tumors

July 13, 2012
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of Clinical Oncology.

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.